TITLE:
IL-17A in Ovarian Cancer
AUTHORS:
Takafumi Watanabe, Masahiko Shibata, Shu Soeda, Shigenori Furukawa, Keiya Fujimori, Koji Kono, Seiichi Takenoshita
KEYWORDS:
Ovarian Cancer, IL-17, VEGF, Immunosuppression, Disease Progression, Malnutrition
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.11 No.10,
October
14,
2020
ABSTRACT: Ovarian cancer is the most common malignant disease
leading to death among women. IL (interleukin)-17A is the most well-studied
member of the IL-17 family, and has been demonstrated to play a critical role
in host defenses against various microbial pathogens, as well as against tissue
inflammation. T-helper (Th)17 cells that produce interleukin (IL)-17A are of particular importance, because IL-17A exerts a wide
variety of biological functions, particularly related to inflammation and the
resultant carcinogenesis, as well as immune
suppression in patients with cancer, and IL-17A-targeted
therapy has been proven to be effective in the treatment of some autoimmune
diseases. The pathogenic features of Th17 and IL-17A cells in cancer are still
controversial, and Th17 cells appear to promote disease progression, as well as
be present in the vicinity of many types of malignant diseases. In cancer
patients, MDSC (myeloid-derived suppressor cells), one of the major
immunosuppressive immature cells, and VEGF (vascular endothelial growth factor)
are reported to correlate each other and strongly connected to IL-17-driven
inflammation and malnutrition. In the present review, the latest advances are
presented about the basic features of IL-17A and Th17. The function of IL-17A
has not been clarified especially in ovarian cancer. This review overview the
basic features of IL-17A and the functions in ovarian cancer as well as in
other malignant and non-malignant diseases. Increasing our understanding of the
interactions between IL-17A and ovarian cancer could lead to new therapeutic
strategies in oncology.